Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Medivir is raising millions. Tetralogic shareholders are watching.
https://m.marketscreener.com/quote/stock/MEDIVIR-AB-PUBL-6491112/news/MEDIVIR-ANNOUNCES-FINAL-OUTCOME-OF-THE-OVERSUBSCRIBED-RIGHTS-ISSUE-AND-RESOLVES-ON-OVER-ALLOTMENT-32398417/
[-chart]www.stockscores.com/chart.asp?TickerSymbol=TLOG&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
I never said I owned more or less than 3 million shares, nor will I share the exact number; I simply suggested that anyone that amasses that quantity or close to it should message me privately (this will benefit all shareholders).
No SEC filing is necessary for owning more than 10% of tetralogic btw; but I appreciate those who file and share their names with me.
As for 6-8 months, Medivir is not the only company that is in play now that benefits tetralogic; that should help point you in the right direction.
Happier days are ahead.
You own over 3 million shares??? If so that’s a lot and more then me. Hahahaha. Question. So since Tetralogic doesn’t require SEC filings, do you have to file for owning that much shares? Just curious. SO what’s the timeline you mentioned of 6-8 months. Does that have to do with the other drug Remetinostat? On the Medivir website they said “A publication of final data is now being prepared.” Glad see you back FlySwater.
Yawn...
Mild accumulation began on December 14th, 3 days after an important announcement; whoever is doing it is smart as they are trying to not raise the price by buying in small batches.
In terms of the recent developments, I was initially annoyed as well; however upon investigation and reflection realized that this is a very good development. Previously our fortunes were tied to Medivir, which is bleeding cash; their new CEO and Chief medical officer are great developments and I was very confident that they would take the company in the right direction and they are. Bottom line is Medivir sid not have the funds or connections to develop Birinapant after the Keytruda debacle; it should have targeted a specific set of colon cancer mutations as 1 patient with those mutations in the trial did do well.
The New company has the funds and desire to make Birinapant into a viable product. Tetralogic renounced their milestone payments with Birinapant in exchange for a larger share of the profits. Yes it will take longer for Birinapant to make us all some $; but remember its not the only egg in the basket.
The recent developments are good.
I own a vast amount of shares and am happy.
Turn those frowns upside down.
As for the individual accumulating the minor amount of shares, message me once you surpass 3 million shares and we can talk.
See you all in about 6-8 months.
Bye~
I think TLOG is going to go. Chart looks ready and volume has been strong.
It seems like someone’s been accumulating a lot of shares. I noticed L2 two weeks and it’s continued. Volume always precedes price. This is interesting and is new from Medivir. This revised deal in my opinion really screws Tetralogic shareholders but at least there’s a substantial company now behind one of our Tetralogic molecules.
“TetraLogic will receive part of total revenues but the main part will accrue to Medivir.”
“In accordance with the recently announced revised agreement with Tetralogic, they will receive a share of future birinapant revenues”
https://www.medivir.com/media/1873/birinapant-igm-webcast-12-jan-final.pdf
Looks like accumulation going on. Hopefully there won’t be another deal that hurts TLOG shareholders. Great for Medivir, questionable for TLOG. Really questioning that recent deal. Just my opinion of course.
??
U
$TLOG Share Structure Outstanding Shares 24,769,083 08/08/2016
Market Cap Market Cap
594,458
01/15/2021
Authorized Shares
Not Available
Outstanding Shares
24,769,083
08/08/2016
SECURITY NOTES
Note = Delisted from Nasdaq on 11-4-2016
correct after sale i thought 'TetraLogic Pharmaceuticals Corp. (TLOG)'
is ah
very valuable shell imho
READING CHANGE TetraLogic Pharmaceuticals Corporation Announces Director Appointment
2017-01-17 14:10:00 - NEW YORK, NY - (PR Distribution™)
TetraLogic Pharmaceuticals Corporation (“TetraLogic” or “Company”) today announced the appointment of Mr. Alexandre Zyngier to its Board of Directors and to its management. The appointment to the Board was effective on December 30, 2016, and, as of December 31, 2016 Mr. Zyngier is the sole director and officer of the Company.
Mr. Zyngier is a Managing Director and founder of Batuta Advisors, firm that pursues investment and advisory opportunities in the distressed and turnaround sectors. Mr. Zyngier has over 20 years of investment, strategy, and operating experience. He currently serves on the boards of directors of Atari SA, AudioEye Inc. (AEYE), GT Advanced Technologies Inc. and Torchlight Energy Resources, Inc (TRCH). Hewas previously Chairman of the Board of Vertis Inc., a director of Island One LLC and Executive Chairman of DTV America Corporation. Mr. Zyngier has worked as a Portfolio Manager, investing in public and private opportunities, at Alden Global Capital, Goldman Sachs & Co., Deutsche Bank Co. and as a sell-side distressed and event-driven analyst at CRT Capital Group. He was also a strategy consultant at McKinsey & Company. Prior to that, he was a technical brand manager at Procter & Gamble, focused on Latin America Beauty Care Products.
On December 29, 2016, TetraLogic announced completion of the sale to Medivir AB (Nasdaq Stockholm: MVIR-B) (“Medivir”) of its SMAC mimetic program, including their clinical stage asset birinapant, and topical HDAC inhibitor, remetinostat (SHAPE).
The Company has voluntarily delisted its Common Stock, from The Nasdaq Global Market and deregistered its Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.
Forward-Looking Statements
Some of the statements in this press release and other written and oral statements made from time to time by TetraLogic and its representatives are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding cost savings and other benefits expected to be derived from the delisting and deregistration and the intent and belief or current expectations of TetraLogic and its management team. Such statements may be identified by the use of words like “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, the negative of these terms or other comparable terminology. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of TetraLogic’s filings with the SEC, including TetraLogic’s Form 10-K for the year ended December 31, 2015 and the Company’s Form 10-Q for the quarter ended September 30, 2016, for information regarding risk factors that could affect TetraLogic’s results. The forward-looking statements contained in this press release speak only as of the date of this press release and TetraLogic undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.
CONTACT: ir@tetralogicpharma.com
$TLOG SALES 12-29-2016 AGREEMENT TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
Date : 12/29/2016 @ 10:30AM
Source : GlobeNewswire Inc.
Stock : NO^TLOG (TLOG)
Quote : 0.1102 0.0 (0.00%) @ 2:05AM
TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
http://ih.advfn.com/p.php?pid=nmona&article=73509938
Updating Review, Waiting for Royalty,huge reading- TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
http://ih.advfn.com/p.php?pid=nmona&article=73509938
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) (“TetraLogic” or “Company”) and its wholly-owned subsidiary
TetraLogic Research and Development Corporation (“TDRC”) today announced that they have completed the sale to
Medivir AB (Nasdaq Stockholm:MVIR) (“Medivir”) of their SMAC mimetic program, including their clinical stage asset birinapant,
and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir (the “Sale”) for a purchase price of
(i) $12 million payable in
cash at closing plus
(ii) milestone payments of up to $153 million based on the development and commercialization of TetraLogic’s
product candidates by
Medivir subject to certain conditions and limitations described in the Asset Purchase Agreement for the Sale
and
(iii) additional earn-out payments based on annual net sales of birinapant,
subject to certain conditions and limitations described
in the Asset Purchase Agreement for the Sale as follows:
the Company will be entitled to 5% of annual net sales from $0 to $500,000,000;
the Company will be entitled to 7.5% of annual net sales from $500,000,000 to $1,000,000,000; and
the Company will be entitled to 10% of annual net sales above $1,000,000,000.
Medivir also assumed certain assumed liabilities.
The transaction was approved by the holders of
TetraLogic’s outstanding convertible debt (the “Senior Notes”) and by a vote of TetraLogic’s stockholders holding a
majority of the shares eligible to vote, at a stockholders’ meeting held on December 29, 2016.
Under its agreement with the holders of Senior Notes, the Company
will use the $12 million cash proceedsreceived at closing of the
Sale to redeem $12 million
in aggregate principal amount of the Senior Notes then outstanding.
The holders of the Senior Notes have also agreed to extend the maturity date of the
Senior Notes to June 15, 2024 and to receive interest payments in additional Senior Notes in lieu of cash.
The Company has voluntarily delisted its Common Stock, from The
Nasdaq Global Market and deregistered its Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.
In connection with the completion of the Sale,
Mr. J. Kevin Buchi,
Dr. Mary Ann Gray,
Mr. Michael Kishbauch,
Mr. Paul Schmitt and
Dr. Andrew Pecora each resigned
as a member of the Board of Directors of the Company, effective December 30, 2016. The resignation was not a result of any disagreement with the
Company on
any matter relating to the Company’s operations, policies or practices. Additionally, effective December 30, 2016, Mr. J. Kevin Buchi resigned as
Chief Executive Officer of the Company, Mr. Richard Sherman resigned
as Senior Vice President, Secretary and General Counsel of the Company,
Mr. Patrick Hutchison resigned as Chief Financial Officer and Treasurer of the Company and Dr. Tony Meehan resigned as Chief Operating Officer of the Company.
In connection with their resignation, each officer entered into a settlement and release agreements pursuant to which each received a
lump sum settlement in the aggregate
amount previously disclosed in the Company’s Form 8-K filed on November 14, 2016.
Forward-Looking Statements
Some of the statements in this press release and other written and oral statements made from time to time by TetraLogic and its representatives are
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements include statements regarding cost savings and other benefits expected to be derived from the delisting and deregistration and the intent
and belief or current expectations of TetraLogic and its management team. Such statements may be identified by the use of words like “anticipate”, “believe”, “estimate”,
“expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, the negative of these terms or other comparable terminology. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the
forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of TetraLogic’s filings with the SEC, including
TetraLogic’s Form 10-K for the year ended December 31, 2015 and the Company’s Form 10-Q for the quarter ended September 30, 2016, for information regarding risk factors that could affect TetraLogic’s results.
The forward-looking statements contained in this press release speak only as of the date of this press release and TetraLogic undertakes no obligation to publicly update any
forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.
CONTACT: Richard L. Sherman General Counsel, TetraLogic Pharmaceuticals Corporation Richard.sherman@tetralogicpharma.com
IS DIS OR ????? AGREEMENT WITH $TLOG BYPASS ????? Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant
Stockholm — Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq: IGMS), will receive global, exclusive development rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells.
The combination of IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) being developed by IGM, and birinapant has been shown to enhance anti-tumor activity preclinically. Medivir will receive an upfront payment of USD 1 million upon signing the agreement, followed by an additional USD 1.5 million when birinapant is included by IGM in clinical phase I studies.
The terms of the agreement furthermore entitle Medivir, should birinapant be successfully developed and approved, to receive milestone payments up to a total of approximately USD 350 million, plus tiered royalties up to mid-teens on net sales.
- “Agreements, such as the one announced today with IGM, continue to be a core component of Medivir’s corporate mission and business model,” said Yilmaz Mahshid, Chief Executive Officer of Medivir. “Today’s announcement further exemplifies our focus and commitment to the development and commercialization of innovative treatments for cancer, and we look forward to IGM’s progress with birinapant in the clinic and beyond.”
- “Based on our in vitro and in vivo models, which have shown remarkable synergy between IGM-8444 and birinapant, we are excited to explore this combination’s potential to deliver superior anti-tumor activity in patients with solid tumors,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
“This agreement is part of a broader strategy to realize the full potential of our IgM drug candidates by maintaining control over the timing and development path of the more promising combinations to emerge from our preclinical and clinical work. We look forward to moving the IGM-8444-birinapant combination into clinical testing to begin validating the significance of targeting DR5 with an IgM antibody in certain combinations and to continuing to explore similar strategic options across our IgM platform.”
In addition to its apoptotic activity, birinapant augments anti-tumor immune system activity.
Through this double action, on both tumor cells and cells of the immune system, birinapant has the potential to improve the treatment of several types of cancer when used in combination with other drugs. IGM-8444 is currently being tested in a phase I dose escalation study in patients with solid and hematologic malignancies.
DR5 is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and is often expressed on the surface of cancer cells.
Subject to regulatory review, IGM hopes to begin the clinical testing of birinapant in combination with IGM-8444 for the treatment of solid cancers later this year.
Conference call for investors, analysts and the media
Presenters: Yilmaz Mahshid, CEO Medivir, Fredrik Öberg, CSO Medivir and Fred Schwarzer, CEO IGM Biosciences.
Time: Tuesday January 12, 2021, at 15.00 CET
Phone numbers for participants from:
Sweden + 46 8 505 583 74
Europe + 44 33 3300 9031
US +1 833 526 8347
The conference call will also be streamed via a link on the website: http://www.medivir.com
The presentation will be available on Medivir’s website after completion of the conference.
For further information, please contact:
Dr Yilmaz Mahshid, CEO, Medivir AB, phone: +46 (0)8 5468 3100.
E-mail: yilmaz.mahshid@medivir.com
Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of the contact person set out above, at 23.59 CET on January 11, 2021.
About birinapant
Birinapant is a SMAC mimetic that was acquired from TetraLogic Pharmaceuticals Corporation (TetraLogic) in 2016 and has since then been developed by Medivir. Medivir recently renegotiated the original agreement with TetraLogic so that the compensation Medivir is obliged to pay in connection with a licensing agreement is based on the distribution of actual future revenues to Medivir.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.
Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
It has the potential to become the first liver-targeted, orally administered drug for patients with HCC.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com
IGM Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements relating to IGM’s plans, expectations and forecasts and to future events. Such forward-looking statements include, but are not limited to, the potential of, and expectations regarding, birinapant,
IGM’s technology platform and antibody drug candidates including IGM-8444 and the combination of birinapant and IGM-8444, the potential safety and efficacy of the combination of birinapant and IGM-8444, statements regarding IGM’s Phase 1 clinical trial of IGM-8444, IGM’s development strategy for IGM-8444 and plans to begin clinical testing of birinapant in combination with IGM-8444 for the treatment of solid cancers,
and statements by the Chief Executive Officers of Medivir and IGM. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including but not limited to:
termination of the license agreement; IGM’s ability to demonstrate the safety and efficacy of IGM-8444 in combination with birinapant; IGM’s ability to successfully and timely advance the combination through preclinical studies and clinical trials; IGM’s ability to enroll patients in its clinical trials; the potential for the results of clinical trials to differ from preclinical or expected results;
the risk of significant adverse events, toxicities or other undesirable side effects; IGM’s ability to successfully manufacture and supply its product candidates, including birinapant and IGM-8444, for clinical trials; the risk that all necessary regulatory approvals cannot be obtained; the risk that the potential benefits of the combination do not outweigh their costs;
potential delays and disruption resulting from the COVID-19 pandemic and governmental responses to the pandemic, including any future impacts to IGM’s operations, the manufacturing of its product candidates, the progression of its clinical trials, enrollment in its current and future clinical trials and on its collaborations and related efforts;
IGM’s early stages of clinical drug development; risks related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; IGM’s ability
to obtain additional capital to finance its operations, if needed; uncertainties related to the projections of the size of patient populations suffering from the diseases IGM is targeting; IGM’s ability to obtain, maintain and protect its intellectual property rights;
developments relating to IGM’s competitors and its industry, including competing product candidates and therapies; risks related to collaborations with third parties, including the risk of the occurrence of any event,
change or other circumstance that could give rise to the termination of any such collaboration; general economic and market conditions;
and other risks and uncertainties, including those more fully described in IGM’s filings with the Securities and Exchange Commission (SEC),
including IGM’s Annual Report on Form 10-K filed with the SEC on March 26, 2020, IGM’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020,
IGM’s Current Report on Form 8-K filed with the SEC on December 7, 2020 and in IGM’s future reports to be filed with the SEC.
Any forward-looking statements contained in this press release speak only as of the date hereof, and IGM specifically disclaims any obligation to update any forward-looking statement, except as required by law.
$TLOG
https://investorshub.advfn.com/TetraLogic-Pharmaceuticals-Corp-TLOG-27741/
$TLOG LONG OVERDUE ROYALTY PAYMENT
01-16-2021
FlySwater - eventually the truth will come out. The agents of manipulation can’t stay anonymous forever.
“While the defendant may have tried to hide behind legal terms and a suit and tie, the jury clearly saw the defendant’s scheme for what it was” - U.S. Attorney Geoffrey S. Berman
You said it perfectly
I’m not sure what to say about this board. The one who posts the most (mick) appears to be a bot, while others are virtually non existent. The two biggest pieces of news to hit Tetralogic in over 4 years and no one even cares enough to discuss??? In my opinion Tetralogic and Medivir have orchestrated a revised deal that harms existing TLOG shareholders. Add in Medivir’s awful outlicense of birinipant, yet this place is crickets. Makes me wonder who is really behind some of these posts. If you don’t care about being run over by extremely questionable deal making, then please sell your shares and bounce. In my opinion.
If TLOG doesn’t have obligations to file with SEC because they are dark filer, then how will they communicate material information to shareholders such as renegotiations, royalty payments etc? In my opinion something doesn’t seem right.
It didn’t make sense why TLOG would renegotiate. Now this news out of Medivir makes sense why they renegotiated and I my opinion this is an awful deal for shareholders. Is Mr. Alexandre Zyngier still the CEO and TLOG board? We now get payments of a payment because birinipant licensing has been reassigned. Maybe time shareholders seek outside assistance?
https://www.prdistribution.com/news/tetralogic-pharmaceuticals-corporation-announces-director-appointment/1426045
https://www.linkedin.com/company/batuta-capital-advisors
This is why the renegotiation happen just the other day. We’ve been cut off at the knees
TetraLogic Pharmaceu (TLOG)
0.01795 ? -0.00685 (-27.62%)
Volume: 16,087 @01/12/21 3:50:39 PM EST
Bid Ask Day's Range
0.0111 0.025 0.01795 - 0.0248
TLOG Detailed Quote
Updating Review, Waiting for Royalty,huge reading- TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
http://ih.advfn.com/p.php?pid=nmona&article=73509938
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) (“TetraLogic” or “Company”) and its wholly-owned subsidiary
TetraLogic Research and Development Corporation (“TDRC”) today announced that they have completed the sale to
Medivir AB (Nasdaq Stockholm:MVIR) (“Medivir”) of their SMAC mimetic program, including their clinical stage asset birinapant,
and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir (the “Sale”) for a purchase price of
(i) $12 million payable in
cash at closing plus
(ii) milestone payments of up to $153 million based on the development and commercialization of TetraLogic’s
product candidates by
Medivir subject to certain conditions and limitations described in the Asset Purchase Agreement for the Sale
and
(iii) additional earn-out payments based on annual net sales of birinapant,
subject to certain conditions and limitations described
in the Asset Purchase Agreement for the Sale as follows:
the Company will be entitled to 5% of annual net sales from $0 to $500,000,000;
the Company will be entitled to 7.5% of annual net sales from $500,000,000 to $1,000,000,000; and
the Company will be entitled to 10% of annual net sales above $1,000,000,000.
Medivir also assumed certain assumed liabilities.
The transaction was approved by the holders of
TetraLogic’s outstanding convertible debt (the “Senior Notes”) and by a vote of TetraLogic’s stockholders holding a
majority of the shares eligible to vote, at a stockholders’ meeting held on December 29, 2016.
Under its agreement with the holders of Senior Notes, the Company
will use the $12 million cash proceedsreceived at closing of the
Sale to redeem $12 million
in aggregate principal amount of the Senior Notes then outstanding.
The holders of the Senior Notes have also agreed to extend the maturity date of the
Senior Notes to June 15, 2024 and to receive interest payments in additional Senior Notes in lieu of cash.
The Company has voluntarily delisted its Common Stock, from The
Nasdaq Global Market and deregistered its Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.
In connection with the completion of the Sale,
Mr. J. Kevin Buchi,
Dr. Mary Ann Gray,
Mr. Michael Kishbauch,
Mr. Paul Schmitt and
Dr. Andrew Pecora each resigned
as a member of the Board of Directors of the Company, effective December 30, 2016. The resignation was not a result of any disagreement with the
Company on
any matter relating to the Company’s operations, policies or practices. Additionally, effective December 30, 2016, Mr. J. Kevin Buchi resigned as
Chief Executive Officer of the Company, Mr. Richard Sherman resigned
as Senior Vice President, Secretary and General Counsel of the Company,
Mr. Patrick Hutchison resigned as Chief Financial Officer and Treasurer of the Company and Dr. Tony Meehan resigned as Chief Operating Officer of the Company.
In connection with their resignation, each officer entered into a settlement and release agreements pursuant to which each received a
lump sum settlement in the aggregate
amount previously disclosed in the Company’s Form 8-K filed on November 14, 2016.
Forward-Looking Statements
Some of the statements in this press release and other written and oral statements made from time to time by TetraLogic and its representatives are
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements include statements regarding cost savings and other benefits expected to be derived from the delisting and deregistration and the intent
and belief or current expectations of TetraLogic and its management team. Such statements may be identified by the use of words like “anticipate”, “believe”, “estimate”,
“expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, the negative of these terms or other comparable terminology. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the
forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of TetraLogic’s filings with the SEC, including
TetraLogic’s Form 10-K for the year ended December 31, 2015 and the Company’s Form 10-Q for the quarter ended September 30, 2016, for information regarding risk factors that could affect TetraLogic’s results.
The forward-looking statements contained in this press release speak only as of the date of this press release and TetraLogic undertakes no obligation to publicly update any
forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.
CONTACT: Richard L. Sherman General Counsel, TetraLogic Pharmaceuticals Corporation Richard.sherman@tetralogicpharma.com
IT DOESN'T APPEAR IN SHAREHOLDERS FAVOR 'TuesdaySmall' on 'TetraLogic Pharmaceuticals Corp. (TLOG)
I’m confused by this news of renegotiated agreement. Who approved this on the Tetralogic side? In 2016 the original transaction was approved “by the holders of TetraLogic’s outstanding convertible debt (the “Senior Notes”) and by a vote of TetraLogic’s stockholders holding a majority of the shares eligible to vote, at a stockholders’ meeting held on December 29, 2016.” Really puzzled how this renegotiation went down. Anyone?
I DID NOT SEE DA NEWS, to 'Flygy481' on 'TetraLogic Pharmaceuticals Corp. (TLOG)'
TetraLogic Pharmaceu (TLOG)
0.018 ? 0.0079 (78.22%)
Volume: 57,250 @01/07/21 2:41:50 PM EST
Bid Ask Day's Range
0.01 0.02 0.011 - 0.019
TLOG Detailed Quote
I’m confused by this news of renegotiated agreement. Who approved this on the Tetralogic side? In 2016 the original transaction was approved “by the holders of TetraLogic’s outstanding convertible debt (the “Senior Notes”) and by a vote of TetraLogic’s stockholders holding a majority of the shares eligible to vote, at a stockholders’ meeting held on December 29, 2016.” Really puzzled how this renegotiation went down. Anyone?
I’m not well-versed with this stuff, but, it almost seems to me like they’ve subtracted ways for us to get a $ payout. Regardless, it’s nice to finally see TLOG in the news after all this time.
I KNOW DIS OVERDUE ROYALTY PAYMENT
What do ya know!? News!
[-chart]www.stockscores.com/chart.asp?TickerSymbol=TLOG&TimeRange=180&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
WKLY
$TLOG LONG OVERDUE ROYALTY PAYMENT
TetraLogic Pharmaceu (TLOG)
0.0108 ? 0.0008 (8.00%)
Volume: 30,984 @12/07/20 12:36:42 PM EST
Bid Ask Day's Range
0.0095 0.016 0.0095 - 0.0108
TLOG Detailed Quote
TetraLogic Pharmaceu (TLOG)
N/A ? N/A (N/A%)
Volume: 0 @-
Bid Ask Day's Range
- - - - -
TLOG Detailed Quote
TetraLogic Pharmaceu (TLOG)
0.0101 ? -0.0001 (-0.98%)
Volume: 2,000 @10/23/20 3:24:30 PM EDT
Bid Ask Day's Range
0.0101 0.025 0.0101 - 0.01445
TLOG Detailed Quote
TetraLogic Pharmaceu (TLOG)
0.02 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
0.015 0.025 - - -
TLOG Detailed Quote
*yawn*
Luckily I dont have much in here, but wonder if the sale will ever benefit us here.
$TLOG NEWS TO UPDATE SHAREHOLDERS
TetraLogic Pharmaceu (TLOG)
0.02 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
0.015 0.026 - - -
TLOG Detailed Quote
TetraLogic Pharmaceu (TLOG)
0.016 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
0.015 0.03 - - -
TLOG Detailed Quote
TetraLogic Pharmaceu (TLOG)
0.016 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
0.015 0.03 - - -
TLOG Detailed Quote
TetraLogic Pharmaceu (TLOG)
0.0229 ? -0.001 (-4.18%)
Volume: 3,300 @07/24/20 2:34:23 PM EDT
Bid Ask Day's Range
0.009 0.0239 0.016 - 0.0229
TLOG Detailed Quote
Followers
|
35
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2001
|
Created
|
01/04/14
|
Type
|
Free
|
Moderators |
Medivir is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer.
To do this efficiently and with a high success rate, we bring together a unique combination of clinical development skills,
a collaborative culture and an extensive industry experience, with a balanced project portfolio.
Medivir is listed on Nasdaq Stockholm's Small Cap list.
UPDATED 04-28-2020SMAC mimetic (Intravenous)
Head & Neck cancer (with radiation)
https://www.medivir.com/our-projects#Partnerships
Read more
Read more
Read more
| |
TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB |
Medivir also assumed certain assumed liabilities.
The transaction was approved by the holders of TetraLogic’s outstanding convertible debt (the “Senior Notes”) and by a vote of TetraLogic’s stockholders
holding a majority of the shares eligible to vote, at a stockholders’ meeting held on December 29, 2016.
Under its agreement with the holders of Senior Notes, the Company will use the $12 million cash proceedsreceived at closing of the Sale to redeem $12 million
in aggregate principal amount of the Senior Notes then outstanding.
The holders of the Senior Notes have also agreed to extend the maturity date of the
Senior Notes to June 15, 2024 and to receive interest payments in additional Senior Notes in lieu of cash.
The Company has voluntarily delisted its Common Stock, from The Nasdaq Global Market and
deregistered its Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.
In connection with the completion of the Sale,
Mr. J. Kevin Buchi,
Dr. Mary Ann Gray,
Mr. Michael Kishbauch,
Mr. Paul Schmitt and
Dr. Andrew Pecora each resigned
as a member of the Board of Directors of the Company, effective December 30, 2016.
The resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Additionally, effective December 30, 2016, Mr. J. Kevin Buchi resigned as Chief Executive Officer of the Company,
Mr. Richard Sherman resigned as Senior Vice President, Secretary and General Counsel of the Company,
Mr. Patrick Hutchison resigned as Chief Financial Officer and Treasurer of the Company and Dr. Tony Meehan resigned as
Chief Operating Officer of the Company. In connection with their resignation, each officer entered into a settlement and release
agreements pursuant to which each received a lump sum settlement in the aggregate
amount previously disclosed in the Company’s Form 8-K filed on November 14, 2016.
Forward-Looking Statements
Some of the statements in this press release and other written and oral statements made from time to time by TetraLogic and its representatives are
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements include statements regarding cost savings and other benefits expected to be derived from the delisting and deregistration and the intent
and belief or current expectations of TetraLogic and its management team.
Such statements may be identified by the use of words like “anticipate”, “believe”, “estimate”,
“expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, the negative of these terms or other comparable terminology. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the
forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of TetraLogic’s filings with the SEC, including
TetraLogic’s Form 10-K for the year ended December 31, 2015 and the Company’s Form 10-Q for the quarter ended September 30, 2016,
for information regarding risk factors that could affect TetraLogic’s results.
The forward-looking statements contained in this press release speak only as of the date of this press release and TetraLogic undertakes no obligation to publicly
update any
forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.
CONTACT: Richard L. Sherman General Counsel, TetraLogic Pharmaceuticals Corporation Richard.sherman@tetralogicpharma.com
ONCOLOGY | PHASE 1 | PHASE 2 | PHASE 3 |
---|---|---|---|
Myelodysplastic Syndromes (MDS) | Birinapant | ||
Cutaneous T-Cell Lymphoma (CTCL) | SHAPE | ||
Ovarian Cancer | Birinapant | ||
INFECTIOUS DISEASE | |||
Hepatitis B |
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |